Oramed inks deal with Medicox for oral insulin in South Korea

14 November 2022

Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) saw its shares rise as much as 3.3% to $7.82 in early trading, after it revealed signing an exclusive commercial distribution agreement for South Korea with Medicox Co, an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.

Under the accord, Medicox will get an exclusive license to apply for regulatory approval for and will distribute Oramed’s oral insulin candidate (ORMD-0801) for 10 years in Korea. ORMD-081 is an oral glucagon-like peptide-1 (GLP-1) analog of exenatide capsule for type 2 diabetes.

Medicox will purchase ORMD-0801 at an agreed transfer price and will additionally pay Oramed up to $18 million, $2 million of which have already been received by Oramed to date, in developmental milestones and up to 15% royalties on gross sales. Medicox will additionally be responsible for gaining regulatory approval in Republic of Korea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK